Literature DB >> 32153002

Screening diabetes mellitus patients for tuberculosis in Southern Nigeria: A pilot study.

Ngozi Ekeke1, Elias Aniwada2, Joseph Chukwu1, Charles Nwafor1, Anthony Meka1, Alphonsus Chukwuka1, Okechukwu Ezeakile1, Adeyemi Ajayi3, Festus Soyinka4, Francis Bakpa5, Victoria Uwanuruochi6, Ezechukwu Aniekwensi7, Chinwe Eze1.   

Abstract

INTRODUCTION: Diabetes mellitus (DM) and tuberculosis (TB) are of great public health importance globally, especially in Sub-Saharan Africa. Tuberculosis is the third cause of death among subjects with non-communicable diseases. DM increases risk of progressing from latent to active tuberculosis. The study aimed to ascertain yield of TB cases and the number needed to screen (NNS) among DM patients.
MATERIAL AND METHODS: Across-sectional study was conducted at 10 health facilities with high DM patient load and readily accessible DOTS center in 6 states of southern region of Nigeria over aperiod of 6 months under routine programme conditions. All patients who gave consent were included in the study. Yield and NNS were calculated using an appropriate formula.
RESULTS: 3 457 patients were screened with amean age (SD) of 59.9 (12.9) years. The majority were male, 2 277 (65.9%). Overall prevalence of TB was 0.8% (800 per 100 000). Sixteen (0.5%) were known TB cases (old cases). There were 221 presumptive cases (6.4%) out of which 184 (83.3%) were sent for Xpert MTB/Rif assay. Eleven (0.3%) new cases of TB were detected, giving additional yield of 40.7% and the number needed to screen (NNS) of 315. All the 11 patients were placed on anti-TB treatment.
CONCLUSIONS: The prevalence of TB among DM patients was higher than in the general population. The yield was also good and comparable to other findings. This underscores the need for institute active screening for TB among DM patients. Further stu-dies are recommended to identify associated factors to guide policy makers in planning and development of TB-DM integrated services.

Entities:  

Keywords:  Nigeriaa; diabetes; number needed to be screened; screening; tuberculosis; yield

Mesh:

Year:  2020        PMID: 32153002     DOI: 10.5603/ARM.2020.0072

Source DB:  PubMed          Journal:  Adv Respir Med        ISSN: 2451-4934


  6 in total

1.  Number needed to screen for TB in clinical, structural or occupational risk groups.

Authors:  F Naufal; L H Chaisson; K O Robsky; P Delgado-Barroso; H S Alvarez-Manzo; C R Miller; A E Shapiro; J E Golub
Journal:  Int J Tuberc Lung Dis       Date:  2022-06-01       Impact factor: 3.427

2.  Incidence and prevalence of pulmonary tuberculosis among patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Qian Wu; Yang Liu; Yu-Bo Ma; Kui Liu; Song-Hua Chen
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

3.  Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.

Authors:  Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne
Journal:  Cochrane Database Syst Rev       Date:  2021-03-23

4.  Integrating tuberculosis and noncommunicable diseases care in low- and middle-income countries (LMICs): A systematic review.

Authors:  Chuan De Foo; Pami Shrestha; Leiting Wang; Qianmei Du; Alberto L García-Basteiro; Abu Saleh Abdullah; Helena Legido-Quigley
Journal:  PLoS Med       Date:  2022-01-18       Impact factor: 11.069

5.  The co-management of tuberculosis-diabetes co-morbidities in Indonesia under the National Tuberculosis Control Program: results from a cross-sectional study from 2017 to 2019.

Authors:  Weixi Jiang; Fauziah Mauly Rahman; Adik Wibowo; Adhi Sanjaya; Permata Imani Ima Silitonga; Shenglan Tang; Qian Long
Journal:  BMC Public Health       Date:  2022-04-08       Impact factor: 3.295

Review 6.  Implementation of the WHO's collaborative framework for the management of tuberculosis and diabetes: a scoping review.

Authors:  Rita Suhuyini Salifu; Mbuzeleni Hlongwa; Khumbulani Hlongwana
Journal:  BMJ Open       Date:  2021-11-17       Impact factor: 3.006

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.